Quality assurance of 3D-CRT: indications and difficulties in their applications.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 18768328)

Published in Crit Rev Oncol Hematol on September 02, 2008

Authors

Luisa Begnozzi1, Marcello Benassi, Mario Bertanelli, Antonio Bonini, Luca Cionini, Leopoldo Conte, Claudio Fiorino, Pietro Gabriele, Gianstefano Gardani, Alessandra Giani, Secondo Magri, Maria Morelli, Brunello Morrica, Patrizia Olmi, Roberto Orecchia, Giovanni Penduzzu, Luigi Raffaele, Antonella Rosi, M Antonella Tabocchini, Riccardo Valdagni, Vincenza Viti

Author Affiliations

1: Servizio di Fisica Sanitaria Ospedale S. Giovanni Calibita, Fatebenefratelli, Roma, Italy.

Articles by these authors

High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86

Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol (2011) 5.00

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48

Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol (2013) 4.21

Breast cancer. Lancet (2005) 3.27

Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07

Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98

Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol (2013) 2.84

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer (2004) 2.82

Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer (2010) 2.62

miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52

Does tumor growth follow a "universal law"? J Theor Biol (2003) 2.47

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47

Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer (2004) 2.46

Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46

Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys (2008) 2.30

Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol (2005) 2.14

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer (2003) 2.11

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int (2010) 2.08

Twenty years of radiobiology in clinical practice: the Italian contribution. Tumori (2015) 1.98

Imatinib mesylate in chordoma. Cancer (2004) 1.94

Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys (2003) 1.88

Chordoma. Curr Opin Oncol (2007) 1.75

Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.68

Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer (2004) 1.61

Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat (2010) 1.59

Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54

miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54

Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol (2009) 1.51

A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys (2005) 1.49

Radiotherapy-induced mandibular bone complications. Cancer Treat Rev (2002) 1.49

Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer (2004) 1.48

Radiation exposure after permanent prostate brachytherapy. Radiother Oncol (2006) 1.47

Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg (2005) 1.47

Axillary radiotherapy instead of axillary dissection: a randomized trial. Italian Oncological Senology Group. Ann Surg Oncol (2002) 1.46

Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.46

Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin. Eur J Nucl Med Mol Imaging (2009) 1.45

Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys (2013) 1.45

Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45

Salvage high dose rate brachytherapy after primary external beam irradiation in localized prostate cancer: a case report. Tumori (2009) 1.44

Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? BJU Int (2014) 1.44

Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol (2013) 1.43

Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys (2004) 1.43

Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med (2010) 1.42

Radiotherapy-related fatigue. Crit Rev Oncol Hematol (2002) 1.40

Radiotherapy-induced thyroid disorders. Cancer Treat Rev (2004) 1.39

Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol (2007) 1.37

Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol (2005) 1.32

Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31

Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer (2009) 1.28

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol (2008) 1.28

Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol (2006) 1.27

IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol (2009) 1.27

Radiotherapy-induced ear toxicity. Cancer Treat Rev (2003) 1.26

Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.26

Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys (2007) 1.23

Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev (2004) 1.21

Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys (2008) 1.21

How do the ASTRO consensus statement guidelines for the application of accelerated partial breast irradiation fit intraoperative radiotherapy? A retrospective analysis of patients treated at the European Institute of Oncology. Int J Radiat Oncol Biol Phys (2012) 1.21

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol (2008) 1.20

Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol (2004) 1.18

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer (2012) 1.18

Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys (2007) 1.17

Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol (2011) 1.16

Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev (2008) 1.14

Nipple-sparing mastectomy--is it worth the risk? Nat Rev Clin Oncol (2011) 1.14

Intraoperative radiation therapy first part: rationale and techniques. Crit Rev Oncol Hematol (2006) 1.13

Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys (2003) 1.13

Nipple-sparing mastectomy in association with intra operative radiotherapy (ELIOT): A new type of mastectomy for breast cancer treatment. Breast Cancer Res Treat (2005) 1.12

Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol (2007) 1.11

What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol (2007) 1.11

The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11

Intraoperative radiation therapy for breast cancer: technical notes. Breast J (2003) 1.10

Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review. Crit Rev Oncol Hematol (2009) 1.10

Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer (2008) 1.10

Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys (2007) 1.09

Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates. Tumori (2007) 1.09

Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol (2006) 1.08

Quality indicators in radiotherapy. Radiother Oncol (2007) 1.08

Real-time tumour tracking in particle therapy: technological developments and future perspectives. Lancet Oncol (2012) 1.07

Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys (2008) 1.07

Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol (2009) 1.06

In regard to Vogelius and Bentzen. Int J Radiat Oncol Biol Phys (2013) 1.05

IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. Breast (2006) 1.04

MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Radiat Oncol Biol Phys (2004) 1.04

Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer. Radiother Oncol (2013) 1.03

The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys (2003) 1.03

Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys (2006) 1.03

Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol (2012) 1.03